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Abstract
Synthetic genetic devices that interface with native cellular pathways can be used to change
natural networks to implement new forms of control and behavior. The engineering of gene
networks has been limited by an inability to interface with native components. We describe a class
of RNA control devices that overcome these limitations by coupling increased abundance of
particular proteins to targeted gene expression events through the regulation of alternative RNA
splicing. We engineered RNA devices that detect signaling through the NF-κB and Wnt signaling
pathways in human cells and rewire these pathways to produce new behaviors, thereby linking
disease markers to noninvasive sensing and reprogrammed cellular fates. Our work provides a
genetic platform that can build programmable sensing-actuation devices enabling autonomous
control over cellular behavior.
Cellular decisions, such as differentiation, response to stress, disease progression, and
apoptosis, depend on regulatory networks that control enzymatic activities, protein
translocation, and genetic responses. Central to the genetic programming of biological
systems is the ability to process information within cellular networks and link this
information to new cellular behaviors, in essence rewiring network topologies. Altered
network topologies have been achieved through engineered transcriptional networks (1, 2)
and signal transduction cascades (3). However, these systems are limited to processing
transcription factor inputs, which represent a small fraction of the human proteome (4, 5), or
require replacing endogenous cellular components. Alternative platforms for constructing
sensing-actuation devices based on the detection of broad classes of proteins will have
widespread applications in basic research, biotechnology, and medicine.
RNA is a promising substrate for platforms to interface with cellular networks because of
the versatile sensing and actuation functions that RNA can exhibit and the ease with which
RNA structures can be designed (6, 7). RNA-based sensing-actuation devices have been
engineered that respond predominantly to externally applied small molecule (6, 8, 9) and
nucleic acid (10–12) inputs and control gene expression through diverse mechanisms. Pre-
mRNA splicing is one such mechanism, in which devices responsive to exogenous small
molecule and protein inputs can regulate splicing events (8, 13). However, protein-
responsive gene regulatory platforms based on programmed alternative splicing must
support modular and extensible input/output functionalities, provide regulatory properties
that translate to control over cell behaviors, and be sensitive to changes in endogenous
protein concentrations or localization. Although RNA aptamers that bind to proteins have
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been generated through in vitro selection methods (14, 15), such protein-sensing
components have not been routinely integrated into RNA-based regulatory devices, leaving
a large number of biological signals currently inaccessible.
We developed a protein-responsive RNA-based regulatory device by integrating RNA
aptamers that bind to protein ligands into key intronic locations of an alternatively spliced
transcript, thus linking intracellular protein concentrations to gene expression events. Our
regulatory platform consists of an output module, a gene of interest (GOI), placed
downstream of the sensing-actuation device, a three-exon, two-intron mini-gene in which
the middle exon is alternatively spliced, or excluded (Fig. 1A). The middle exon contains a
stop codon, such that expression of the GOI is high when the exon is excluded. Control is
exerted by the input module, composed of an RNA aptamer that senses changes in nuclear
protein concentrations whereby ligand binding to the aptamer alters the splicing pattern,
likely through steric hindrance or recruitment of components involved in spliceosome site
(ss) recognition (Fig. 1A, B) (16).
We systematically analyzed the device architecture to determine the intron positions that
enabled aptamer-mediated protein-responsive regulation of alternative splicing. We inserted
the aptamer for the bacteriophage coat protein MS2 (17) at 6 positions in each intron (1–12)
of the SMN1 mini-gene (18) (Fig. 1C and Fig. S1A), and linked the device to the gene
encoding green fluorescent protein (GFP). The SMN1 mini-gene was selected because key
regulatory sequences are located in exon regions (19), such that insertion of synthetic
sequences into intronic regions is not likely to strongly affect splicing patterns. Human
embryonic kidney (HEK)-293 cell lines that stably expressed these devices or the
corresponding negative controls expressing mutant aptamers (SOM text S1) displayed
differences in fluorescence compared to cells expressing a device containing no aptamer
sequence, with insertion at most positions causing increased exon exclusion (Fig. S1B and
C), indicating that secondary structure can modulate splicing patterns.
To examine protein-specific effects on splicing, cell lines were transfected with a plasmid
encoding the MS2 coat protein fused to fluorescent protein DsRed and a Simian virus 40
(SV40) nuclear localization signal (MS2-DsRed) (Fig. 1C and Fig. S1D). Integration of
aptamers into 6 positions resulted in increases in fluorescence (P < 0.05, Student’s t-test)
and 3 positions resulted in decreases in fluorescence (P < 0.05) relative to that of cell lines
expressing DsRed. Control experiments showed that these effects were specific to the wild-
type aptamer (Fig. 1,D and E, Fig. S1E, and Table S1). Transcript isoform analysis by
quantitative real-time polymerase chain reaction (qRT-PCR) confirmed the effect on
splicing (Fig. 1E and Fig. S1F), and there was a significant correlation between splicing
patterns and fluorescence (P ≪ 0.01, Anova). Although the regulatory effects of the devices
were modest (~2- to 4-fold), these effects are comparable to those in other splicing (20) and
RNA regulatory (21) systems that have key roles in controlling biological processes. We
selected positions 3, 6, and 10 as points of input module integration for device tailoring on
the basis of their relative amount of protein-mediated splicing regulation and location
relative to splicing motifs (3’ ss, 5’ ss, branch point, and polypyrimidine tract).
To investigate the modularity of the input processing function of our RNA devices and the
ability to detect nuclear localized proteins resulting from activated signaling pathways, we
built devices with aptamers that bind the subunits p50 (22, 23) and p65 (24) of the
transcription factor NF-κB inserted into position 3 (Fig. 2A). NF-κB p50 and p65 dimers
have an important role in disease by binding to κB sites in promoters or enhancers of genes
participating in immune and inflammatory responses, cell adhesion, proliferation, and
apoptosis (24). NF-κB signaling and subsequent translocation of p50 and p65 to the nucleus
was induced in cell lines stably expressing the NF-κB devices with tumor necrosis factor
Culler et al. Page 2
Science. Author manuscript; available in PMC 2011 September 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
alpha (TNF-α) (25). The p65-3 device displayed increased gene expression (P < 0.01),
corresponding to an increase in exon exclusion as a result of p65 binding to the sensor,
whereas the p50-3 devices exhibited decreased gene expression (P < 0.05) and exon
exclusion as a result of p50 binding to the sensor (Fig. 2,B and C, Fig. S2A, and Table S2).
Controls with mutant aptamer devices showed that responses were specific to the wild-type
aptamer sequences. Cell lines expressing the p50-responsive devices and a p50-DsRed
fusion exhibited decreases in fluorescence when compared to cells expressing DsRed (Fig.
2D, Fig. S2B, and Table S3), supporting that the response observed under TNF-α
stimulation is directly mediated by p50 binding. The differing output signals from the p65-
and p50-responsive devices may be due to differences in aptamer binding (24), aptamer
structure, or interactions of p65 and p50 with spliceosomal components (SOM text S2).
We also inserted aptamers that recognize the signaling protein β-catenin (26) into sites 3 and
6 to build β-catenin-responsive devices (Fig. 2E). β-catenin is a central component of the
Wnt signaling pathway and is localized to the nucleus upon pathway activation to aid in the
transcription of genes that regulate cell growth, differentiation, and tumorigenesis (26). We
examined the effect of stimulating the β-catenin pathway with leukotriene D4 (LTD4) on the
response of our engineered β-catenin-responsive devices. The β-cat-6 device exhibited
increased gene expression (P < 0.05), corresponding to an increase in exon exclusion (Fig.
2F, Fig. S2C, and Table S4), whereas the β-cat-3 device did not respond to LTD4
stimulation. Control experiments demonstrated that the β-cat-6 device response was specific
to the wild-type aptamer sequences. Results from the MS2, NF-κB, and β-catenin studies
demonstrate that particular protein ligands can have distinct positional and functional effects
on splicing, such that aptamer position and the target protein provide device tuning
capability. These studies verify the flexibility of our synthetic devices to be interfaced with
cellular signaling pathways and their ability to detect disease biomarkers and link this
detection to regulated gene expression events.
To examine the extension of our device platform to multi-input processing, we constructed
devices containing combinations of the wild-type and mutant MS2 aptamers in positions 3
and 10 (Fig. 3A). Devices containing the wild-type aptamer in either position displayed
significant increases in gene expression (P < 0.01) and exon exclusion in the presence of
MS2-DsRed compared to that in the absence of ligand (Fig. 3B, Fig. S3A, and Table S5). A
device with aptamers in both positions showed a ~30–45% increase in gene expression and
exon exclusion compared to that of the single-aptamer devices. We also built multi-input
devices to detect heterologous MS2-DsRed and endogenous NF-κB p50 (Fig. 3C). We
inserted the wild-type and mutant p50(1) and MS2 aptamers into sites 3 and 10,
respectively. TNF-α stimulation led to a decrease in gene expression and exon exclusion,
whereas expression of MS2-DsRed led to a significant increase in gene expression (P <
0.05) and exon exclusion from this device (Fig. 3D, Fig. S3B and C, and Table S6). The
device response in the presence of both ligands was greater than the sum of the individual
ligand output signals, suggesting that the combined inputs have a synergistic effect on the
output signal. These studies indicate that our device platform can support combinatorial
regulation of gene expression in response to multiple protein inputs.
To examine whether our protein-responsive RNA devices can be used to regulate cell-fate
decisions, we developed devices that integrated across two therapeutic inputs – increased
signaling through a disease-associated pathway and the presence of an exogenously-applied,
inactive “pro-drug” - to trigger targeted cell death (Fig. 4A). We constructed β-catenin- and
NF-κB-responsive devices that trigger apoptosis by replacing the output module with a gene
encoding the herpes simplex thymidine kinase (HSV-TK) (Fig. 4B and C). HSV-TK confers
sensitivity to the pro-drug ganciclovir (GCV), which induces apoptosis (27) and has been
used in clinical trials to treat tumors (28). Cells stably expressing the β-cat-6 and p65-3
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devices exhibited increased sensitivity to GCV under pathway stimulation (Fig. S4A and B)
and a cell survival of ~20% at 100 µg/ml GCV (P < 0.01) (Fig. 4D), similar to that of cells
overexpressing HSV-TK (Fig. S4C). Cells expressing the devices in the absence of pathway
stimulation and mutant devices under pathway stimulation displayed no observable
phenotypic effects and survival rates between 60–90% at 100 µg/ml GCV. We demonstrated
the modularity of the output function of the device platform by replacing the output module
with the proapoptotic gene Puma (Fig. S5).
These results demonstrate that our RNA devices can effectively rewire signaling through
disease-associated pathways to trigger apoptosis using clinically-relevant genetic systems.
There was a slight reduction in survival in cells expressing our devices in the absence of
pathway stimulation, which may reflect effects of high GCV concentrations on cell viability
(Fig. S4D) (29) and basal expression of HSV-TK from our devices. Possible therapeutic
utility and safety of these targeted cell death devices is supported by effective cell-killing
efficacy in the presence of both inputs and minimal background activity in the absence of
one or both inputs. Our results demonstrate that synthetic RNA controllers with moderate
gene regulatory activities (~2–4-fold) can achieve substantial alterations in downstream
functional behaviors through their coupling to potent genetic targets, and effects that are
amplified through associated cellular pathways.
Our system demonstrates that heterologous and endogenous proteins not associated with
splicing regulation can be directed to alter splicing patterns through synthetic protein-
binding sequences. In contrast to protein-based transcriptional control systems, RNA-based
systems present advantages in enabling response to proteins other than transcription factors,
direct tailoring of input/output processing functions without device redesign, extension to
combinatorial processing, and practical implementation in clinical applications (9, 30). The
extension of our framework to the processing of multiple protein inputs can be used to
engineer RNA-based devices with sophisticated information processing activities and to
design and build complex regulatory networks to interrogate and program cellular function.
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Fig. 1.
An alternative splicing-based RNA control device translates protein inputs to targeted gene
expression outputs. (A) Platform composition of an RNA control device based on alternative
splicing. The input module, consisting of an RNA-based protein sensor or aptamer, detects
changes in nuclear protein concentrations. The sensor transmits information on binding
events to the actuator module, consisting of a three-exon, two-intron mini-gene where the
alternatively spliced exon contains a stop codon. The actuator controls the expression of the
output module, consisting of a gene of interest (GOI). The three modules are physically
linked in a transcript to form the assembled RNA control device. (B) Mechanism of RNA
device function. A 3’ ss device is shown, where the input module is located in the intron
upstream of the alternative exon and binding of the protein input to the sensor alters the
splicing pattern by either enhancing (green) or suppressing (red) alternative exon inclusion.
Exclusion of the alternative exon results in removal of the stop codon upstream of the GOI,
thereby increasing the gene expression output from the device. (C) Determination of optimal
input module location within intronic sequence space of the regulatory device. The MS2
aptamer was inserted at 12 intronic positions spaced by 15-nts flanking the alternatively
spliced exon. (D) Fluorescence images of the MS2-responsive devices. The increased
fluorescence output from an MS2-responsive device is specific to the MS2-DsRed protein
input and the wild-type MS2 aptamer in position 3 (MS2-3). (E) The response of the MS2-
responsive device to the MS2-DsRed protein is affected by the location of the input module.
For all activities reported as relative expression (fold), the ratio of the mean GFP levels of
the wild-type RNA device in the presence of ligand (MS2-DsRed) to the absence of ligand
(DsRed) is normalized to the same ratio for the mutant device. Transcript isoform analysis
of the MS2-responsive devices with qRT-PCR supported the gene expression data (bottom
panel). For all qRT-PCR data reported as relative excl/incl (fold), the ratio of the mean
expression levels of the exon 7 excluded isoform to the exon 7 included isoform for the
wild-type device in the presence of ligand to the absence of ligand is normalized to the same
ratio for the mutant device. For all reported activities, mean expression levels from two
independent experiments are shown. Error bars represent +/− s.d. from mean values. P-
values derived from the Student’s t-test are as follows: *P < 0.05 and **P < 0.01.
Unnormalized expression levels for all devices are provided in Tables S1 to S6.
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Fig. 2.
RNA control devices detect endogenous protein inputs and signaling through native
pathways. (A) Mechanism of the NF-κB-responsive device based on TNF-α stimulation (20
ng/ml) of the NF-κB pathway. Ligand binding to the TNF-α receptor leads to activated
signaling and translocation of p50 and p65 into the nucleus. The NF-κB-responsive devices
contain NF-κB p65 (p65-3) or p50 (p50(1)-3 and p50(2)-3) aptamers inserted into position
3. (B) Phase (top) and fluorescence (bottom) images of the NF-κB p65-responsive devices.
The increased fluorescence output from a NF-κB-responsive device is specific to the
pathway stimulation and the wild-type p65 aptamer in position 3 (p65-3). (C) NF-κB-
responsive devices exhibited responses to TNF-α stimulation at the level of gene expression
(left panel) and splicing pattern (right panel). For all data, relative expression (fold) was
determined as described in Fig. 1F. qRT-PCR data is reported as relative excl/incl, the ratio
of the mean expression levels of the exon 7 excluded isoform to the exon 7 included isoform
for the wild-type device relative to the same ratio for the mutant device under the indicated
ligand condition. (D) Mechanism of the NF-κB p50-responsive device based on a p50-
DsRed protein input and corresponding device response. The NF-κB p50-responsive devices
exhibited responses to a heterologous p50-DsRed protein similar to that observed with TNF-
α stimulation. Activities were reported as relative expression by taking the ratio of the mean
GFP levels of the wild-type RNA device to that from the mutant device under the indicated
ligand condition. (E) Mechanism of the β-catenin-responsive device based on LTD4
stimulation (80 nM) of the Wnt pathway. LTD4 stimulation leads to stabilization of β-
catenin and accumulation in the nucleus. The β-catenin-responsive devices contain the β-
catenin aptamer in positions 3 (β-cat-3) and 6 (β-cat-6). (F) β-catenin-responsive devices
exhibited responses to LTD4 stimulation at the level of gene expression (left panel) and
splicing pattern (right panel).
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Fig. 3.
RNA devices implement combinatorial control schemes through multi-input processing. (A)
Mechanism of the MS2 multi-input processing regulatory device. Wild-type and mutant
MS2 aptamers were inserted into positions 3 and 10. (B) The MS2 multi-input processing
device responds to the heterologous MS2-DsRed protein to increase the gene expression
output (top panel). Transcript isoform analysis of the MS2 multi-input processing device
supports gene expression data (bottom panel). For all data, relative expression (fold) and
relative ratios of exon excluded to included transcript isoforms (fold) were determined as
described in Fig. 1F. (C) The MS2 / NF-κB p50 multi-input processing regulatory device
allows integration of complex input signals and amplification of device response. The NF-
κB p50 and MS2 aptamers were inserted into positions 3 and 10, respectively. (D) The
MS2 / NF-κB p50 multi-input processing device responds to both inputs to increase the gene
expression output (top panel). Transcript isoform analysis of the MS2 / NF-κB p50 multi-
input processing device supports gene expression data (bottom panel).
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Fig. 4.
RNA devices detect endogenous markers of disease and trigger targeted cell death. (A)
Functional representation of a targeted therapeutic device that integrates across two
therapeutic inputs – disease biomarker and an exogenously-applied, inactive pro-drug - to
trigger targeted cell death. (B, C) Mechanisms of the β-catenin- (β-cat-6) (B) and NF-κB-
responsive (p65-3) (C) devices fused to a suicide gene therapy output module (HSV-TK),
which control cell survival in response to detection of disease markers and GCV, a pro-drug
trigger. (D) Dose-response curves of cell survival percentages for the β-catenin- and NF-κB-
responsive devices fused to HSV-TK indicate a decrease in cell survival as a result of
increased signaling through the targeted pathway and the presence of GCV. For all reported
data, the mean cell survival levels from two independent experiments are shown.
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